ClinicalTrials.gg
Active, not recruitingNCT06797297Updated Nov 2, 2026

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

A Phase 2 interventional study of IBI363 and Pembrolizumab in Melanoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Now Active, not recruitingPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Enrollment
25th of 189
203 · median 50
Started
2025
with 22 others
Phase 2
75 of 203
30 open now
Primary completion
2026-12
later than 38 of 94 live
Registered
158th of 203
by date

Among the 203 studies in Melanoma with a site in China, this one is the 25th largest by enrollment of the 189 interventional ones that give a count, is one of 23 that started in 2025, is one of 75 in phase 2, reaches primary completion later than 38 of the 94 other live ones, and was the 158th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic mucosal or acral melanoma who had not previously received systemic therapy.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed unresectable, locally advanced or mucosal or acral-type melanoma, according to the American Joint Committee on Cancer (AJCC) 8th edition stage III-IV.
  2. No prior systemic treatment for unresectable or metastatic melanoma; Prior or neoadjuvant therapy (except for disease progression to unresectable or metastatic melanoma during adjuvant or neoadjuvant therapy or within 6 months after treatment discontinuation) was permitted.
  3. Have at least one (target lesion) according to v1.1. For lesions that have previously received radiotherapy or intratumoral injection, measurable lesions that progress to the criteria specified in RECIST1.1 after treatment may be considered.

    The target lesions of this study must be measured by imaging (enhanced CT or MRI. Plain scan CT or MRI can be accepted after communication with the sponsor if the subjects are allergic to contrast media or have other conditions that are not suitable for enhanced CT or MRI).

    Skin lesions or other superficial sites that cannot be repeatedly measured by imaging can only be used as non-target lesions.

  4. The Physical Status Score (ECOG PS) is 0 or 1.
  5. Expected survival time no less than 3 months.
  6. Female subjects of childbearing age or male subjects whose partner is a female of childbearing age agree to strictly use effective throughout the treatment period and for 6 months after the treatment period.
  7. Breastfeeding women must agree to strictly refrain from breastfeeding during the entire treatment period and for 6 months after the treatment period.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or plan to become pregnant within 6 months before, during, or after the last dose of the study drug.
  2. Active or symptomatic central nervous system
  3. Any of the following hematological abnormalities were present at baseline * (within 7 days before the first administration of the study drug) :

    \<90 g/L The absolute count of neutrophils (ANC) was \<1.5×10\^9/L count \<100×10\^9/L

  4. Any of the following serum biochemical abnormalities are present at baseline (within 7 days before the first dose) :

    Total >1.5× (ULN); (AST) or Alanine aminotransferase (ALT) >3×ULN; For liver metastasis, AST or ALT > 5.0×ULN; With serum Creatinine >1.5×ULN or Clearance of Creatinine (CCr) \<45 mL/min, CCr (using actual body weight) was calculated using formula (Appendix 3).

    Albumin \<30 g/L.

  5. Any of the following coagulation parameters are abnormal at baseline (within 7 days before the first dose) :

    International normalizaed ratio () >1.5×ULN (>3×ULN if receiving steady dose anticoagulant therapy); Partial thromboplastin time (PTT) (or activated partial thromboplastin time, [activated partial thromboplastin time, PTT) aPTT]) >1.5×ULN (>3×ULN if receiving steady dose anticoagulant therapy).

  6. There is a history of active thrombosis or deep vein thrombosis or pulmonary embolism in the 4 weeks prior to initial administration of the investigatory drug, unless the disease is adequately treated and is considered stable by the investigator.
  7. Uncontrolled bleeding or a known tendency to bleed.
  8. Cardiovascular and cerebrovascular diseases of significant clinical significance.
  9. History of interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-related pneumonia, radiation pneumonia, etc. requiring hormone or other treatment, as well as severe abnormal lung function or other forms of restrictive lung disease.
  10. An active disease requiring systemic treatment (e.g. with disease-modifying drugs, corticosteroids, or ) has occurred within 2 years prior to first administration. Replacement therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Experimental: IBI363

    Biological: IBI363

  • Active comparator
    Active Comparator: Pembrolizumab

    Biological: Pembrolizumab

Interventions

  • BiologicalIBI363

    a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

  • BiologicalPembrolizumab

    Pembrolizumab is a humanized monoclonal anti-PD1 antibody

06

What researchers measure

Primary outcomes

  1. IRRC-Progression Free Survival(PFS)

    Progression Free Survival assessed by Independent Radiology Review Committee (IRRC-PFS), Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: up to 2 years

Secondary outcomes

  1. INV-Progression Free Survival(PFS)

    Progression Free Survival assessed by Investigator, Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: up to 2 years

  2. Objective Response Rate (ORR)

    Objective response rate (ORR) in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 2 years

  3. Duration of Response (Duration Of Response)

    DOR in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 2 years

  4. Disease Control Rate (DCR)

    DCR in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 2 years

  5. Time to Response (TTR)

    TTR in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 2 years

  6. Overall Survival (OS)

    Overall survival in two arms

    Time frame: up to 2 years

  7. safety indicators during the treatment

    Number of participants with Adverse Event (AE), Treatment Emergent Adverse Event (TEAE), Immune-related AE (irAE), Serious Adverse Event (SAE), treatment-emergent AE leading to treatment termination, death, and related with investigational agent

    Time frame: up to 2 years

07

Study locations

31 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 22 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Mar 2026 → Dec 2026 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 28, 2025
StartActual
Feb 24, 2025
Primary completionEst.
Dec 31, 2026was Mar 2026
CompletionEst.
Dec 31, 2027was Jun 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 2, 2026
Sites
7 sites added, 7 sites removed
Show 7 added (7 China)
  • Beijing Jishuitan Hospital, Capital Medical University · Beijing, China
  • Peking University Cancer Hospital & Institute, Beijing, China, · Beijing, China
  • Chongqing University Cancer Hospital · Chongqing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
  • Second Affiliated Hospital of Xi'an Jiaotong University · Xi’an, China
  • Tianjin Cancer Hospital · Tianjin, China
  • The Affiliated Cancer Hospital of Xinjiang Medical University · Ürümqi, China
Show 7 removed
  • Beijing Jishuitan Hospital, Capital Medical University · Beijing, China
  • Peking University Cancer Hospital & Institute, Beijing, China, · Beijing, China
  • Chongqing University Cancer Hospital · Chongqing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
  • Second Affiliated Hospital of Xi'an Jiaotong University · Xi'an, China
  • Tianjin Cancer Hospital · Tianjin, China
  • The Affiliated Cancer Hospital of Xinjiang Medical University · Urumqi, China
Nov 2, 2026
Primary completion
Mar 31, 2026→Dec 31, 2026
Nov 2, 2026
Study completion
Jun 30, 2027→Dec 31, 2027
Nov 2, 2026
Enrollment
180 (estimated)→203 (actual)
Nov 2, 2026
Eligibility
Revised
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Active, not recruiting
    7 sites added, 7 sites removed
    Show 7 added (7 China)
    • Beijing Jishuitan Hospital, Capital Medical University · Beijing, China
    • Peking University Cancer Hospital & Institute, Beijing, China, · Beijing, China
    • Chongqing University Cancer Hospital · Chongqing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    • Second Affiliated Hospital of Xi'an Jiaotong University · Xi’an, China
    • Tianjin Cancer Hospital · Tianjin, China
    • The Affiliated Cancer Hospital of Xinjiang Medical University · Ürümqi, China
    Show 7 removed
    • Beijing Jishuitan Hospital, Capital Medical University · Beijing, China
    • Peking University Cancer Hospital & Institute, Beijing, China, · Beijing, China
    • Chongqing University Cancer Hospital · Chongqing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    • Second Affiliated Hospital of Xi'an Jiaotong University · Xi'an, China
    • Tianjin Cancer Hospital · Tianjin, China
    • The Affiliated Cancer Hospital of Xinjiang Medical University · Urumqi, China
    Primary completion Mar 31, 2026→Dec 31, 2026
    Study completion Jun 30, 2027→Dec 31, 2027
    Enrollment 180 (estimated)→203 (actual)
    Eligibility Revised
    + 5 other changes: index terms, verification date, oversight details, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06797297
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Feb 24, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Start the discussion